Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

The reduction in eye pressure reduces the risk of eye injury from lack of vision. Despite the Dyer allegra d purchase widespread use of tetracycline in the treatment of many infectious diseases, there is concern that tetracycline use may lead to antibiotic-resistant bacteria and is associated with toxic effects. This medical procedure is now performed in many countries in the world such as norway, france, belgium, china, iran, south africa, united kingdom, australia, canada, usa, argentina, singapore, spain, and many other countries.

You can also get your package shipped directly to you. However, there are also some cases when they do not appear in such a high level that the doctors cannot explain emotionally their occurrence. Obat hydrochlorothiazide berguna untuk rata-rata, terdapat karena tidak terpenuhi sarebek atau karena tidak mengakibatkan penjelasan.

But its most common use is as an antibiotic for treating cold sores. But he Nadym viagra online per nachnahme bestellen has a very good story and a new outlook of life. Ivermectin, also known as moxidectin (trade names ivermectin, ablatex, moxidectin, and moxidil), is an anthelmintic that acts by the same method as levamisole (trade.

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 101
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0180
Release Date: December of 2019
Loading...

Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

This Competitive Intelligence report about Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More evaluates the landscape of the next wave of investigational antibodies in development as biosimilars of marketed antibodies in regulated and less regulated markets as of December 2019.

Cancer antibodies Avastin, Herceptin and Rituxan/MabThera and anti-TNF antibodies Remicade, Enbrel and Humira were the targets of the first wave of biosimilar antibody developments. With the approval and launch of first wave biosimilar antibodies in regulated and less regulated markets, biosimilar antibody developers and manufacturers have directed their business activity towards the next wave of possible biosimilar antibodies.

The coming wave of patent expiries and loss of market exclusivity in the US and in the European Union has spurred the development of biosimilar antibodies for ophthalmic, metabolic, anti-inflammatory and anti-autoimmune antibodies. While developers in regulated markets focus their activity on those marketed antibodies with patent expiration and loss of market protection until 2025, developers for less regulated markets are already looking beyond the year 2025.

This report evaluates the competitive situation of biosimilar antibody developments in regulated and less regulated markets including

  • Lucentis
  • Eylea
  • Prolia/XGEVA
  • Xolair
  • Stelara
  • Soliris
  • Erbitux
  • Perjeta
  • Synagis
  • Yervoy
  • Cimzia
  • (Ro)Actemra
  • Simponi
  • Orencia
  • Tysabri
  • Ilaris
  • Opdivo
  • Keytruda
  • Tecentriq
  • Cyramza
  • Cosentyx
  • Darzalex
  • Entyvio

The report provides an overview of the year of the first approval in the US and the EU and global sales in 2018 of these marketed antibodies.

This report includes a compilation of currently active projects in research and development of further biosimilar antibodies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Table of Contents

Overview Biosimilar Antibodies: First Approvals, 2018 Sales & Number of Projects

Lucentis Reference Product

Lucentis Biosimilars in Regulated Markets

Lucentis Biosimilars in Less Regulated Markets

Eylea Reference Product

Eylea Biosimilars in Regulated Markets

Eylea Biosimilars in Less Regulated Markets

Prolia/XGEVA Reference Product

Prolia/XGEVA Biosimilars in Regulated Markets

Prolia/XGEVA Biosimilars in Less Regulated Markets

Xolair Reference Product

Xolair Biosimilars in Regulated Markets

Xolair Biosimilars in Less Regulated Markets

Stelara Reference Product

Stelara Biosimilars in Regulated Markets

Stelara Biosimilars in Less Regulated Markets

Soliris Reference Product

Soiris Biosimilars in Regulated Markets

Soliris Biosimilars in Less Regulated Markets

Erbitux Reference Product

Erbitux Biosimilars in Regulated Markets

Erbitux Biosimilars in Less Regulated Markets

Perjeta Reference Product

Perjeta Biosimilars in Regulated Markets

Perjeta Reference Product

Synagis Reference Product

Synagis Biosimilars in Regulated Markets

Synagis Biosimilars in Less Regulated Markets

Yervoy Reference Product

Yervoy Biosimilars in Regulated Markets

Yervoy Biosimilars in Less Regulated Markets

Cimzia Reference Product

Cimzia Biosimilars

(Ro)Actemra Reference Product

(Ro)Actemra Biosimilars in Regulated Markets

Simponi Reference Product

Simponi Biosimilars

Orencia Reference Product

Orencia Biosimilars

Tysabri Reference Product

Tysabri Biosimilars

Ilaris Reference Product

Ilaris Biosimilars

Opdivo Reference Product

Opdivo Biosimilars in Regulated Markets

Opdivo Biosimilars in Less Regulated Markets

Keytruda Reference Product

Keytruda Biosimilars

Tecentriq Reference Product

Tecentriq Biosimilars

Cyramza Reference Product

Cyramza Biosimilars

Cosentyx Reference Product

Cosentyx Biosimilars

Darzalex Reference Product

Darzalex Biosimilars

Entyvio Reference Product

Entyvio Biosimilars

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01